1 Ocak 2010 Dergi makalesi Açık Erişim

Barbai, V. H.; Ujhelyi, E.; Szlavik, J.; Vietorisz, I.; Varga, L.; Fey, E.; Fust, G.; Banhegyi, D.

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Barbai, V. H.</dc:creator>
  <dc:creator>Ujhelyi, E.</dc:creator>
  <dc:creator>Szlavik, J.</dc:creator>
  <dc:creator>Vietorisz, I.</dc:creator>
  <dc:creator>Varga, L.</dc:creator>
  <dc:creator>Fey, E.</dc:creator>
  <dc:creator>Fust, G.</dc:creator>
  <dc:creator>Banhegyi, D.</dc:creator>
  <dc:date>2010-01-01</dc:date>
  <dc:description>P&gt;Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-1 infected patients is well documented and generally used, but there is limited information about the changes of acute-phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly active anti-retroviral therapy (HAART) treatment, with undetectable viral load, but low CD4+ cell count (&lt; 300/mu l), have been treated with 3 center dot 6 M IU Proleukine (R) administered twice daily by subcutaneous injection over 5 days. C-reactive protein (CRP), d-dimer, C3, C9, C1-inh and alpha-2HS glycoprotein levels were measured immediately before IL-2 administration, as well as on day 5 and 2-3 weeks thereafter. After IL-2 administration, both mean d-dimer and CRP levels increased significantly (P &lt; 0 center dot 001), but returned (P &lt; 0 center dot 001) to baseline within the subsequent 2-3 weeks. Alpha-2HS glycoprotein decreased immediately after IL-2 administration. No significant differences were detected in the levels of C3, C9 and C1-inh. A significant, positive correlation (r = 0 center dot 5178, P = 0 center dot 0008) was ascertained between the changes of CRP level, measured immediately before as well as 5 days after IL-2 administration, and changes in CD4 T cell counts measured 2-3 weeks before and after treatment, respectively. IL-2 administration induces rapid elevation of two major APPs (CRP, d-dimer). The positive correlation observed between the changes of CRP levels and CD4+ cell counts after IL-2 administration may indicate that the abrupt, but transitory overproduction of CRP might contribute to the CD4+ cell count-increasing effect of the drug and/ or may be associated with serious side effects.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/27023</dc:identifier>
  <dc:identifier>oai:zenodo.org:27023</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>CLINICAL AND EXPERIMENTAL IMMUNOLOGY 161(1) 134-141</dc:source>
  <dc:title>Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>